Limits...
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.

Butrous G - Glob Cardiol Sci Pract (2014)

Bottom Line: Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions.In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

View Article: PubMed Central - PubMed

ABSTRACT
Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions. In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

No MeSH data available.


Related in: MedlinePlus

The chemical structure of the cGMP (brown arrow indicates phosphodiester bond). The lower panel shows the chemical structure of sildenafil and vardenfil. Notice the similarity in structure, except the nitrogen atom's position and the change of sildenafil's piperazinering from a methyl group to an ethyl group (green arrows). The bottom structure is for tadalafil which is more different the other PDE5 inhibitors, which explains the binding affinity to the PDE5 enzyme and thus its longer half-life.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4352681&req=5

fig1: The chemical structure of the cGMP (brown arrow indicates phosphodiester bond). The lower panel shows the chemical structure of sildenafil and vardenfil. Notice the similarity in structure, except the nitrogen atom's position and the change of sildenafil's piperazinering from a methyl group to an ethyl group (green arrows). The bottom structure is for tadalafil which is more different the other PDE5 inhibitors, which explains the binding affinity to the PDE5 enzyme and thus its longer half-life.

Mentions: Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men,1 as well as congestive heart failure,2 chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases,3,4, diabetes5 and various other conditions.6 In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases (PVDs).7 The PDE5 has been targeted by specific inhibitors (mostly cGMP analogs), such as sildenafil, vardenfil, and tadalafil (See Figure 1).8


The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.

Butrous G - Glob Cardiol Sci Pract (2014)

The chemical structure of the cGMP (brown arrow indicates phosphodiester bond). The lower panel shows the chemical structure of sildenafil and vardenfil. Notice the similarity in structure, except the nitrogen atom's position and the change of sildenafil's piperazinering from a methyl group to an ethyl group (green arrows). The bottom structure is for tadalafil which is more different the other PDE5 inhibitors, which explains the binding affinity to the PDE5 enzyme and thus its longer half-life.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4352681&req=5

fig1: The chemical structure of the cGMP (brown arrow indicates phosphodiester bond). The lower panel shows the chemical structure of sildenafil and vardenfil. Notice the similarity in structure, except the nitrogen atom's position and the change of sildenafil's piperazinering from a methyl group to an ethyl group (green arrows). The bottom structure is for tadalafil which is more different the other PDE5 inhibitors, which explains the binding affinity to the PDE5 enzyme and thus its longer half-life.
Mentions: Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men,1 as well as congestive heart failure,2 chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases,3,4, diabetes5 and various other conditions.6 In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases (PVDs).7 The PDE5 has been targeted by specific inhibitors (mostly cGMP analogs), such as sildenafil, vardenfil, and tadalafil (See Figure 1).8

Bottom Line: Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions.In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

View Article: PubMed Central - PubMed

ABSTRACT
Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions. In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

No MeSH data available.


Related in: MedlinePlus